Lipoprotein Apheresis: First FDA Indicated Treatment for Elevated Lipoprotein(a)
Anne Nugent, Jessica V. Gray, Lauryn K. Gorby, Patrick M. Moriarty
Abstract
Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD) for which no commercially available pharmacotherapy exists. Currently, lipoprotein apheresis (LA) is the only available therapeutic option for patients with elevated Lp(a) and established CVD and in 2020, the FDA revised approval criteria for LA acknowledging elevated Lp(a) in its guidelines.
Topics & Concepts
MedicineLipoprotein(a)ApheresisLipoproteinPharmacotherapyAtherosclerotic cardiovascular diseaseInternal medicineRisk factorDiseasePharmacologyIntensive care medicineCholesterolPlateletLipoproteins and Cardiovascular HealthAntiplatelet Therapy and Cardiovascular DiseasesPharmaceutical Economics and Policy